4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-24-024990
Director sold 10,420 shares at $28.17 ($293,557)
- Director acquired 10,420 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ballal Rahul D. Director | 2024-10-08 | Option exercise 10b5-1 | +6,314 | $19.68 | $124,260 | 28,655 | D |
| Ballal Rahul D. Director | 2024-10-08 | Option exercise 10b5-1 | +4,106 | $5.52 | $22,665 | 32,761 | D |
| Ballal Rahul D. Director | 2024-10-08 | Sale 10b5-1 | −10,420 | $28.17 | $293,557 | 22,341 | D |
| Derivatives | |||||||
| Ballal Rahul D. Director | 2024-10-08 | Option exercise · Stock Option (right to buy) 10b5-1 | −6,314 | 69,428 | D | ||
| Ballal Rahul D. Director | 2024-10-08 | Option exercise · Stock Option (right to buy) 10b5-1 | −4,106 | 12,322 | D | ||
| Open-market sales · 10,420 sh · avg $28.17 · $293,557 | |||||||
Loading xslF345X05/form4-10112024_121018.xml…